Cargando…
First case of COVID‐19 infused with hESC derived immunity‐ and matrix‐regulatory cells
Autores principales: | Wu, Jun, Hu, Zhongjie, Wang, Liu, Tan, Yuanqing, Hou, Wei, Li, Zhongwen, Gao, Tingting, Fan, Jiaqi, Guo, Baojie, Dai, Huaping, Li, Wei, Hao, Jie, Jin, Ronghua, Hu, Baoyang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7645847/ https://www.ncbi.nlm.nih.gov/pubmed/33107123 http://dx.doi.org/10.1111/cpr.12943 |
Ejemplares similares
-
Phase 1 trial for treatment of COVID‐19 patients with pulmonary fibrosis using hESC‐IMRCs
por: Wu, Jun, et al.
Publicado: (2020) -
Infusion of hESC derived Immunity‐and‐matrix regulatory cells improves cognitive ability in early‐stage AD mice
por: Liu, Jing, et al.
Publicado: (2021) -
Hyaluronate supports hESC‐cardiomyocyte cell therapy for cardiac regeneration after acute myocardial infarction
por: Tan, Yuanqing, et al.
Publicado: (2020) -
A Chemical Recipe for Generation of Clinical-Grade Striatal Neurons from hESCs
por: Wu, Menghua, et al.
Publicado: (2018) -
Genome editing HLA alleles for a pilot immunocompatible hESC line in a Chinese hESC bank for cell therapies
por: Ji, Tian‐Tian, et al.
Publicado: (2023)